SG10201702950TA - Inhibitors of hepatitis c virus - Google Patents
Inhibitors of hepatitis c virusInfo
- Publication number
- SG10201702950TA SG10201702950TA SG10201702950TA SG10201702950TA SG10201702950TA SG 10201702950T A SG10201702950T A SG 10201702950TA SG 10201702950T A SG10201702950T A SG 10201702950TA SG 10201702950T A SG10201702950T A SG 10201702950TA SG 10201702950T A SG10201702950T A SG 10201702950TA
- Authority
- SG
- Singapore
- Prior art keywords
- hepatitis
- virus
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261667806P | 2012-07-03 | 2012-07-03 | |
US201361798524P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201702950TA true SG10201702950TA (en) | 2017-06-29 |
Family
ID=48803614
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201702950TA SG10201702950TA (en) | 2012-07-03 | 2013-07-02 | Inhibitors of hepatitis c virus |
SG10201912269YA SG10201912269YA (en) | 2012-07-03 | 2013-07-02 | Inhibitors of hepatitis c virus |
SG11201408739VA SG11201408739VA (en) | 2012-07-03 | 2013-07-02 | Inhibitors of hepatitis c virus |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912269YA SG10201912269YA (en) | 2012-07-03 | 2013-07-02 | Inhibitors of hepatitis c virus |
SG11201408739VA SG11201408739VA (en) | 2012-07-03 | 2013-07-02 | Inhibitors of hepatitis c virus |
Country Status (41)
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
BR112015007879A2 (pt) | 2012-10-19 | 2017-07-04 | Bristol Myers Squibb Co | inibidores do vírus da hepatite c |
EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
JP2015508418A (ja) | 2013-01-31 | 2015-03-19 | ギリアド ファーマセット エルエルシー | 2種の抗ウイルス化合物のコンビナトリアル製剤 |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
JP6511432B2 (ja) * | 2013-03-15 | 2019-05-15 | ギリアード サイエンシーズ, インコーポレイテッド | C型肝炎ウイルスの大環状二環式阻害剤 |
EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
CA2934049A1 (en) * | 2013-12-23 | 2015-07-02 | Gilead Sciences, Inc. | Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide |
MX2016008452A (es) * | 2013-12-23 | 2016-10-14 | Gilead Sciences Inc | Sintesis de un tripeptido macrociclico inhibidor de ns3 de virus de la hepatitis c. |
US10059969B1 (en) | 2014-10-03 | 2018-08-28 | Abbvie Inc. | Process for the preparation of (S)-2-amino-non-8-enoic acid |
HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
WO2016132805A1 (ja) * | 2015-02-16 | 2016-08-25 | セントラル硝子株式会社 | 含フッ素α-ケトカルボン酸エステル類の実用的な製造方法 |
WO2017184670A2 (en) | 2016-04-22 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating zika virus infections |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
SG11201809893WA (en) | 2016-05-27 | 2018-12-28 | Gilead Sciences Inc | Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors |
BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
JOP20190052A1 (ar) | 2016-09-22 | 2019-03-21 | Astrazeneca Ab | 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز |
TWI693286B (zh) | 2017-02-01 | 2020-05-11 | 美商艾伯維有限公司 | (±)-2-(二氟甲基)-1-(烷氧羰基)-環丙烷甲酸及(±)-2-(乙烯基)-1-(烷氧羰基)-環丙烷甲酸之酶催化製法 |
JP6804790B1 (ja) | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | N4−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
CN111018795B (zh) * | 2019-12-25 | 2023-03-28 | 上海彩迩文生化科技有限公司 | 一种碱性条件下合成喹喔啉-3-酮的方法 |
US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
EP4382529A1 (en) | 2022-12-07 | 2024-06-12 | Bayer Consumer Care AG | A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030091946A (ko) | 2000-12-12 | 2003-12-03 | 쉐링 코포레이션 | C형 간염 바이러스의 ns3-세린 프로테아제억제제로서의 디아릴 펩티드 |
IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
JP4271148B2 (ja) | 2002-05-20 | 2009-06-03 | ブリストル−マイヤーズ スクイブ カンパニー | 置換シクロアルキルp1’c型肝炎ウイルスインヒビター |
ATE503764T1 (de) | 2002-05-20 | 2011-04-15 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
ES2350201T3 (es) | 2002-05-20 | 2011-01-20 | Bristol-Myers Squibb Company | Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c. |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
ATE422895T1 (de) | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
ES2335887T3 (es) | 2003-04-18 | 2010-04-06 | Enanta Pharmaceuticals, Inc. | Compuestos macrociclicos de quinoxalinilo que inhiben las serina proteasas de la hepatitis c. |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
AU2004240704B9 (en) | 2003-05-21 | 2009-10-22 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2005274700B2 (en) | 2004-07-16 | 2011-11-10 | Gilead Sciences, Inc. | Antiviral compounds |
WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
CA2606195C (en) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
EP2305697A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
CA2615896C (en) * | 2005-08-01 | 2012-11-13 | Merck & Co., Inc. | Macrocyclic peptides as hcv ns3 protease inhibitors |
CN101233148A (zh) * | 2005-08-01 | 2008-07-30 | 默克公司 | 作为hcv ns3蛋白酶抑制剂的大环肽 |
NZ568135A (en) | 2005-10-11 | 2011-06-30 | Array Biopharma Inc | Macrocyclic compounds and methods for inhibiting hepatitis C viral replication |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
EP2079480B1 (en) | 2006-10-24 | 2013-06-05 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
WO2008051475A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
AU2007309546A1 (en) | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
MX2009004556A (es) | 2006-10-27 | 2009-07-10 | Merck & Co Inc | Inhibidores de la proteasa ns3 del hcv. |
CA2667032A1 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20080287449A1 (en) | 2007-04-26 | 2008-11-20 | Deqiang Niu | Aza-tripeptide hepatitis c serine protease inhibitors |
NZ581606A (en) | 2007-05-03 | 2012-06-29 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
AP2009005057A0 (en) | 2007-05-10 | 2009-12-31 | Array Biopharma Inc | Novel peptide inhibitors of hepatitis c virus replication |
US20090005387A1 (en) | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
MX2009013827A (es) | 2007-06-29 | 2010-03-01 | Gilead Sciences Inc | Compuestos antivirales. |
AP2009005073A0 (en) | 2007-06-29 | 2009-12-31 | Gilead Sciences Inc | Antiviral compounds |
AU2008277377B2 (en) | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
WO2009014730A1 (en) | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
JP2010540549A (ja) | 2007-09-24 | 2010-12-24 | アキリオン ファーマシューティカルズ,インコーポレーテッド | ウイルス複製阻害剤としての尿素含有ペプチド |
US8106059B2 (en) | 2007-10-24 | 2012-01-31 | Virobay, Inc. | Substituted pyrazines that inhibit protease cathepsin S and HCV replication |
WO2009055335A2 (en) | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
WO2009070692A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
WO2009070689A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
CA2708042A1 (en) | 2007-12-05 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl derivatives |
WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
NZ586231A (en) | 2007-12-21 | 2012-12-21 | Avila Therapeutics Inc | HCV protease inhibitors comprising a functionalised proline derivative |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
CN102036966A (zh) | 2008-01-24 | 2011-04-27 | 益安药业 | 作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽 |
AR070413A1 (es) | 2008-02-04 | 2010-04-07 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de proteasa de serina |
WO2009108507A1 (en) | 2008-02-25 | 2009-09-03 | Merck & Co., Inc. | Therapeutic compounds |
US8431733B2 (en) | 2008-03-12 | 2013-04-30 | Virobay, Inc. | Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives |
MX2010010276A (es) | 2008-03-20 | 2011-03-25 | Enanta Pharm Inc | Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c. |
EA201071034A1 (ru) | 2008-04-15 | 2011-06-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликаций вируса гепатита с |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009134624A1 (en) | 2008-04-28 | 2009-11-05 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US8211891B2 (en) | 2008-04-30 | 2012-07-03 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors |
ES2392611T3 (es) * | 2008-07-22 | 2012-12-12 | Merck Sharp & Dohme Corp. | Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC |
BRPI0916609A2 (pt) | 2008-08-07 | 2015-08-04 | Hoffmann La Roche | Processo para a preparação de um macrociclo |
CA2734744A1 (en) | 2008-08-20 | 2010-02-25 | Michael Eissenstat | Hcv protease inhibitors |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
WO2010033466A1 (en) | 2008-09-16 | 2010-03-25 | Phenomix Corporation | Macrocyclic inhibitors of hepatitis c protease |
MX2011002828A (es) | 2008-09-16 | 2011-04-05 | Boehringer Ingelheim Int | Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv. |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
MX2011004007A (es) | 2008-10-15 | 2011-05-19 | Intermune Inc | Peptidos antivirales terapeuticos. |
WO2010048468A1 (en) | 2008-10-23 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Deuterated macrocyclic inhibitors of viral ns3 protease |
CA2743912A1 (en) | 2008-11-20 | 2010-05-27 | Achillion Pharmaceuticals, Inc. | Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus |
KR20110087297A (ko) | 2008-11-21 | 2011-08-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 경구 투여용의 강력한 hcv 억제제의 약제학적 조성물 |
US20100272674A1 (en) | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN102245598B (zh) | 2008-12-10 | 2014-01-29 | 艾其林医药公司 | 病毒复制抑制剂4-氨基-4-氧代丁酰基肽环状类似物 |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AR074670A1 (es) | 2008-12-19 | 2011-02-02 | Gilead Sciences Inc | Inhibidores de la proteasa ns3 del vhc virus de la hepatitis c |
KR101734507B1 (ko) | 2008-12-23 | 2017-05-11 | 얀센 파마슈티칼스 인코포레이티드 | Hcv의 마크로시클릭 프로테아제 억제제를 제조하기 위한 방법 및 중간체 |
MX2011012155A (es) | 2009-05-13 | 2012-02-28 | Enanta Pharm Inc | Compuestos macrociclicos como inhibidores del virus de hepatitis c. |
US8703700B2 (en) | 2009-05-22 | 2014-04-22 | Sequoia Pharmaceuticals, Inc. | Bimacrocylic HCV NS3 protease inhibitors |
EP2459582B1 (en) | 2009-07-30 | 2015-05-27 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
JP2013500961A (ja) | 2009-07-31 | 2013-01-10 | カディラ ヘルスケア リミテッド | グルコキナーゼ(gk)アクチベーターとしての置換ベンズアミド誘導体 |
CN102470158A (zh) | 2009-08-27 | 2012-05-23 | 默沙东公司 | 制备丙型肝炎病毒的蛋白酶抑制剂的工艺方法 |
WO2011038293A1 (en) | 2009-09-28 | 2011-03-31 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis c virus replication |
TW201116540A (en) | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
US9193740B2 (en) | 2009-10-19 | 2015-11-24 | Enanta Pharmaceuticals, Inc. | Bismacrocyclic compounds as hepatitis C virus inhibitors |
JP5717768B2 (ja) | 2010-03-10 | 2015-05-13 | アッヴィ・バハマズ・リミテッド | 固体組成物 |
US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
CN103025736B (zh) | 2010-06-07 | 2016-07-06 | Abbvie公司 | 大环的丙型肝炎丝氨酸蛋白酶抑制剂 |
WO2012019299A1 (en) | 2010-08-11 | 2012-02-16 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
US20120094897A1 (en) | 2010-09-15 | 2012-04-19 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
SI2618831T1 (sl) | 2010-09-21 | 2016-06-30 | Enanta Pharmaceuticals, Inc. | Makrociklični inhibitorji proteaze HCV na osnovi prolina |
EP2618665A4 (en) | 2010-09-21 | 2014-08-20 | Merck Sharp & Dohme | HCV NS3 PROTEASE INHIBITORS |
WO2012040242A1 (en) | 2010-09-22 | 2012-03-29 | Intermune, Inc. | Substituted proline inhibitors of hepatitis c virus replication |
WO2012047764A1 (en) | 2010-10-04 | 2012-04-12 | Intermune, Inc. | Therapeutic antiviral peptides |
WO2012054874A1 (en) | 2010-10-22 | 2012-04-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
BR112013010836A2 (pt) | 2010-11-01 | 2019-09-24 | Genoscience Pharma | inibidores específicos de ns3 protease de hcv |
US9120818B2 (en) | 2010-12-14 | 2015-09-01 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP6110846B2 (ja) | 2011-05-27 | 2017-04-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2012171332A1 (zh) | 2011-06-16 | 2012-12-20 | 爱博新药研发(上海)有限公司 | 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用 |
US8912141B2 (en) | 2011-06-23 | 2014-12-16 | Panmed Ltd. | Treatment of hepatitis C virus |
BR112014003802A2 (pt) | 2011-08-19 | 2017-06-13 | Merck Sharp & Dohme | composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento |
WO2013066753A1 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Compositions useful for the treatment of viral diseases |
US9328138B2 (en) | 2011-11-15 | 2016-05-03 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
EA201400808A1 (ru) | 2012-01-12 | 2015-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Стабилизированные фармацевтические составы сильнодействующего ингибитора вируса гепатита с |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
JP6511432B2 (ja) | 2013-03-15 | 2019-05-15 | ギリアード サイエンシーズ, インコーポレイテッド | C型肝炎ウイルスの大環状二環式阻害剤 |
-
2013
- 2013-02-07 UA UAA201413651A patent/UA119315C2/uk unknown
- 2013-07-02 RS RS20161182A patent/RS55494B1/sr unknown
- 2013-07-02 KR KR1020167008636A patent/KR102040023B1/ko active Protection Beyond IP Right Term
- 2013-07-02 EP EP16190694.6A patent/EP3159345B1/en active Active
- 2013-07-02 ME MEP-2016-245A patent/ME02547B/me unknown
- 2013-07-02 LT LTEP16190694.6T patent/LT3159345T/lt unknown
- 2013-07-02 HU HUE13739324A patent/HUE032404T2/en unknown
- 2013-07-02 NZ NZ703064A patent/NZ703064A/en unknown
- 2013-07-02 WO PCT/US2013/049119 patent/WO2014008285A1/en active Application Filing
- 2013-07-02 HU HUE16190694A patent/HUE042345T2/hu unknown
- 2013-07-02 KR KR1020147037149A patent/KR101610575B1/ko active Protection Beyond IP Right Term
- 2013-07-02 EP EP13739324.5A patent/EP2870160B1/en active Active
- 2013-07-02 DK DK16190694.6T patent/DK3159345T3/en active
- 2013-07-02 EA EA201492214A patent/EA027390B1/ru unknown
- 2013-07-02 SI SI201330345A patent/SI2870160T1/sl unknown
- 2013-07-02 AU AU2013286729A patent/AU2013286729B2/en active Active
- 2013-07-02 BR BR122021012378-0A patent/BR122021012378B1/pt active IP Right Grant
- 2013-07-02 EP EP20191299.5A patent/EP3825312A1/en not_active Withdrawn
- 2013-07-02 SI SI201331350T patent/SI3159345T1/sl unknown
- 2013-07-02 KR KR1020197031860A patent/KR20190124346A/ko not_active Application Discontinuation
- 2013-07-02 EA EA201790661A patent/EA033961B1/ru unknown
- 2013-07-02 CN CN201380042756.6A patent/CN104540832B/zh active Active
- 2013-07-02 AP AP2014008166A patent/AP3903A/en active
- 2013-07-02 PL PL16190694T patent/PL3159345T3/pl unknown
- 2013-07-02 LT LTEP13739324.5T patent/LT2870160T/lt unknown
- 2013-07-02 IN IN2598MUN2014 patent/IN2014MN02598A/en unknown
- 2013-07-02 SG SG10201702950TA patent/SG10201702950TA/en unknown
- 2013-07-02 JP JP2015520657A patent/JP6025977B2/ja active Active
- 2013-07-02 DK DK13739324.5T patent/DK2870160T3/en active
- 2013-07-02 ES ES16190694T patent/ES2716138T3/es active Active
- 2013-07-02 PE PE2014002587A patent/PE20150204A1/es active IP Right Grant
- 2013-07-02 CN CN201610474633.5A patent/CN106117309B/zh active Active
- 2013-07-02 MD MDA20140136A patent/MD4602B1/ro not_active IP Right Cessation
- 2013-07-02 PT PT137393245T patent/PT2870160T/pt unknown
- 2013-07-02 US US13/934,090 patent/US9296782B2/en active Active
- 2013-07-02 PL PL13739324T patent/PL2870160T3/pl unknown
- 2013-07-02 AR ARP130102368 patent/AR091661A1/es active IP Right Grant
- 2013-07-02 ES ES13739324.5T patent/ES2605383T3/es active Active
- 2013-07-02 ME MEP-2019-66A patent/ME03362B/me unknown
- 2013-07-02 EP EP18215386.6A patent/EP3492464B1/en active Active
- 2013-07-02 SG SG10201912269YA patent/SG10201912269YA/en unknown
- 2013-07-02 SG SG11201408739VA patent/SG11201408739VA/en unknown
- 2013-07-02 MX MX2014015846A patent/MX360597B/es active IP Right Grant
- 2013-07-02 CA CA2877005A patent/CA2877005C/en active Active
- 2013-07-02 NZ NZ739248A patent/NZ739248A/en unknown
- 2013-07-02 UY UY0001034888A patent/UY34888A/es not_active Application Discontinuation
- 2013-07-02 MY MYPI2014003617A patent/MY173342A/en unknown
- 2013-07-02 RS RS20190303A patent/RS58409B1/sr unknown
- 2013-07-02 PT PT16190694T patent/PT3159345T/pt unknown
- 2013-07-02 ES ES18215386T patent/ES2827300T3/es active Active
- 2013-07-02 US US14/412,331 patent/US20150175655A1/en not_active Abandoned
- 2013-07-02 MD MDA20180040A patent/MD20180040A2/ro not_active Application Discontinuation
- 2013-07-02 BR BR112014033080-8A patent/BR112014033080B1/pt active IP Right Grant
- 2013-07-02 TW TW102123626A patent/TWI602822B/zh active
-
2014
- 2014-12-22 PH PH12014502862A patent/PH12014502862B1/en unknown
- 2014-12-28 IL IL236500A patent/IL236500B/en active IP Right Grant
- 2014-12-31 CL CL2014003634A patent/CL2014003634A1/es unknown
-
2015
- 2015-01-13 CO CO15005727A patent/CO7160104A2/es unknown
- 2015-01-20 EC ECIEPI20152066A patent/ECSP15002066A/es unknown
- 2015-02-03 CR CR20150045A patent/CR20150045A/es unknown
- 2015-10-13 HK HK15109972.6A patent/HK1209416A1/xx unknown
- 2015-11-04 HK HK15110878.9A patent/HK1210151A1/xx unknown
- 2015-11-10 JP JP2015220577A patent/JP2016041743A/ja not_active Withdrawn
-
2016
- 2016-01-13 AU AU2016200201A patent/AU2016200201A1/en not_active Abandoned
- 2016-01-15 US US14/996,961 patent/US20160130300A1/en not_active Abandoned
- 2016-02-03 AU AU2016200670A patent/AU2016200670A1/en not_active Abandoned
- 2016-06-17 US US15/185,273 patent/US9655944B2/en active Active
- 2016-10-12 PH PH12016502040A patent/PH12016502040A1/en unknown
- 2016-10-24 HR HRP20161379TT patent/HRP20161379T1/hr unknown
- 2016-12-22 CY CY20161101337T patent/CY1118379T1/el unknown
- 2016-12-27 SM SM201600470T patent/SMT201600470B/it unknown
-
2017
- 2017-04-14 US US15/488,035 patent/US20170290827A1/en not_active Abandoned
- 2017-05-23 IL IL252446A patent/IL252446A0/en active IP Right Grant
- 2017-06-13 AU AU2017203984A patent/AU2017203984B2/en active Active
-
2018
- 2018-06-11 US US16/005,111 patent/US10335409B2/en active Active
- 2018-06-12 JP JP2018111786A patent/JP2018154651A/ja not_active Withdrawn
- 2018-09-04 IL IL26158118A patent/IL261581B/en active IP Right Grant
- 2018-11-08 MX MX2018013668A patent/MX2018013668A/es unknown
-
2019
- 2019-03-19 CY CY20191100328T patent/CY1121418T1/el unknown
- 2019-03-25 HR HRP20190578TT patent/HRP20190578T1/hr unknown
- 2019-05-10 US US16/409,610 patent/US10603318B2/en active Active
- 2019-08-29 AU AU2019222909A patent/AU2019222909B2/en active Active
- 2019-09-25 IL IL26966219A patent/IL269662A/en unknown
-
2020
- 2020-05-04 PH PH12020550552A patent/PH12020550552A1/en unknown
- 2020-05-15 JP JP2020085702A patent/JP2020143107A/ja active Pending
-
2021
- 2021-06-23 AU AU2021204238A patent/AU2021204238A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269662A (en) | Hepatitis C virus inhibitors | |
ZA201306720B (en) | Hepatitis c virus inhibitors | |
HK1185763A1 (zh) | 丙型肝炎病毒抑制劑 | |
IL229270A0 (en) | Hepatitis c virus inhibitors | |
EP2768517A4 (en) | HEPATITIS C-VIRUS HEMMER | |
ZA201309356B (en) | Hepatitis c virus inhibitors | |
HK1212332A1 (en) | Hepatitis c virus inhibitors | |
PL2850075T3 (pl) | Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu c |